NCT06758713View on ClinicalTrials.gov

Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Multiple MyelomaB-cell LymphomaHematological Malignancy
Interventions
BIOLOGICAL

CAR-T

CAR T-cell therapy involves autologous chimeric antigen receptor T-cells, capable of targeting human B cell maturation antigen (BCMA) ,CD19 or CD-7 etc. target molecules of other hematologic malignancies.

Trial Locations (1)

510630

RECRUITING

The Third Affiliated Hospital of Southern Medical University, Guangzhou

All Listed Sponsors
lead

The Third Affiliated Hospital of Southern Medical University

OTHER_GOV